Tvardi Therapeutics Ord Shs
TVRD4.323USD
+0.033+0.78%
Market hours （ET）Quotes delayed by 15 min
--Market Cap
LossP/E TTM
More Details of Company
Tvardi Therapeutics Ord Shs Info
Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -
Company Executives of Tvardi Therapeutics Ord Shs
Name
Name/Position
Position
Shareholding
Change
Dr. Susan Shiff, Ph.D.
Dr. Susan Shiff, Ph.D.
Independent Director
Independent Director
5.61K
--
Dr. Yixin (Joseph) Chen, Ph.D.
Dr. Yixin (Joseph) Chen, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Dan Conn, J.D.
Mr. Dan Conn, J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
--
--
Mr. Sujal A. Shah
Mr. Sujal A. Shah
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Independent Director
Independent Director
--
--
Mr. Wallace Hall
Mr. Wallace Hall
Independent Director
Independent Director
--
--
Dr. Jeffrey (Jeff) Larson, Ph.D.
Dr. Jeffrey (Jeff) Larson, Ph.D.
Senior Vice President - Research & Development
Senior Vice President - Research & Development
--
--
Dr. John Kauh, M.D.
Dr. John Kauh, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Stephen O'Brien, CPA
Mr. Stephen O'Brien, CPA
Vice President - Finance, Corporate Controller
Vice President - Finance, Corporate Controller
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Susan Shiff, Ph.D.
Dr. Susan Shiff, Ph.D.
Independent Director
Independent Director
5.61K
--
Dr. Yixin (Joseph) Chen, Ph.D.
Dr. Yixin (Joseph) Chen, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Dan Conn, J.D.
Mr. Dan Conn, J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
--
--
Mr. Sujal A. Shah
Mr. Sujal A. Shah
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Dec 9
Currency: USDUpdated: Tue, Dec 9
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2021
By BusinessUSD
Name
Revenue
Proportion
Other revenue
1.32M
51.50%
Collaborative revenue
1.20M
46.63%
Clinical compound revenue
48.00K
1.87%
Commercial supply revenue
0.00
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Other revenue
1.32M
51.50%
Collaborative revenue
1.20M
46.63%
Clinical compound revenue
48.00K
1.87%
Commercial supply revenue
0.00
0.00%
Shareholding Stats
Updated: 18 hours ago
Updated: 18 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sporos Bioventures LLC
8.93%
Solas Tvardi Sidecar LLC
8.11%
Slate Path Capital LP
7.51%
Tweardy (David John)
6.92%
DePinho (Ronald A)
6.67%
Other
61.86%
Shareholders
Shareholders
Proportion
Sporos Bioventures LLC
8.93%
Solas Tvardi Sidecar LLC
8.11%
Slate Path Capital LP
7.51%
Tweardy (David John)
6.92%
DePinho (Ronald A)
6.67%
Other
61.86%
Shareholder Types
Shareholders
Proportion
Corporation
19.23%
Individual Investor
17.56%
Hedge Fund
11.09%
Investment Advisor
10.97%
Investment Advisor/Hedge Fund
5.38%
Research Firm
0.51%
Bank and Trust
0.09%
Pension Fund
0.03%
Insurance Company
0.02%
Other
35.12%
Institutional Shareholding
Updated: Tue, Dec 9
Updated: Tue, Dec 9
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
201
2.63M
28.09%
+309.90K
2025Q3
240
2.63M
28.09%
+211.56K
2025Q2
255
1.96M
20.86%
+381.35K
2025Q1
304
216.78K
14.22%
-690.19K
2024Q4
335
370.98K
24.35%
-475.57K
2024Q3
349
383.52K
25.18%
-554.07K
2024Q2
363
500.51K
32.96%
-507.31K
2024Q1
376
666.56K
43.91%
-330.38K
2023Q4
385
694.09K
45.87%
-306.90K
2023Q3
396
782.27K
52.08%
-231.29K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sporos Bioventures LLC
837.64K
8.95%
--
--
May 30, 2025
Solas Tvardi Sidecar LLC
761.29K
8.13%
--
--
May 30, 2025
Slate Path Capital LP
704.12K
7.51%
--
--
Sep 30, 2025
Tweardy (David John)
649.05K
6.93%
+649.05K
--
May 30, 2025
DePinho (Ronald A)
626.19K
6.67%
-151.45K
-19.48%
Sep 30, 2025
The Vanguard Group, Inc.
419.17K
4.47%
+20.76K
+5.21%
Sep 30, 2025
Tweardy (Samuel David)
315.66K
3.36%
-631.32K
-66.67%
Jul 07, 2025
BlackRock Institutional Trust Company, N.A.
305.94K
3.26%
+58.48K
+23.63%
Sep 30, 2025
Vifor (International), Ltd
205.47K
2.19%
-1.00
-0.00%
Apr 16, 2025
683 Capital Management LLC
176.03K
1.88%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 9
Updated: Tue, Dec 9
Name
Proportion
Invesco Dorsey Wright SmallCap Momentum ETF
0.04%
Texas Capital Texas Small Cap Equity Index ETF
0.01%
iShares Russell 2000 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
Amplify Seymour Cannabis ETF
0%
iShares Russell 3000 ETF
0%
Global X Russell 2000 ETF
0%
Schwab U.S. Small-Cap ETF
0%
ProShares UltraPro Russell2000
0%
View more
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.04%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Amplify Seymour Cannabis ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 14, 2025
Merger
3→1
Date
Type
Ratio
Apr 14, 2025
Merger
3→1
FAQs
Who are the top five shareholders of Tvardi Therapeutics Ord Shs?
The top five shareholders of Tvardi Therapeutics Ord Shs are:
Sporos Bioventures LLC holds 837.64K shares, accounting for 8.95% of the total shares.
Solas Tvardi Sidecar LLC holds 761.29K shares, accounting for 8.13% of the total shares.
Slate Path Capital LP holds 704.12K shares, accounting for 7.51% of the total shares.
Tweardy (David John) holds 649.05K shares, accounting for 6.93% of the total shares.
DePinho (Ronald A) holds 626.19K shares, accounting for 6.67% of the total shares.
Sporos Bioventures LLC holds 837.64K shares, accounting for 8.95% of the total shares.
Solas Tvardi Sidecar LLC holds 761.29K shares, accounting for 8.13% of the total shares.
Slate Path Capital LP holds 704.12K shares, accounting for 7.51% of the total shares.
Tweardy (David John) holds 649.05K shares, accounting for 6.93% of the total shares.
DePinho (Ronald A) holds 626.19K shares, accounting for 6.67% of the total shares.
What are the top three shareholder types of Tvardi Therapeutics Ord Shs?
The top three shareholder types of Tvardi Therapeutics Ord Shs are:
Sporos Bioventures LLC
Solas Tvardi Sidecar LLC
Slate Path Capital LP
Sporos Bioventures LLC
Solas Tvardi Sidecar LLC
Slate Path Capital LP
How many institutions hold shares of Tvardi Therapeutics Ord Shs (TVRD)?
As of 2025Q4, 201 institutions hold shares of Tvardi Therapeutics Ord Shs, with a combined market value of approximately 2.63M, accounting for 28.09% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.00%.
What is the biggest source of revenue for Tvardi Therapeutics Ord Shs?
In FY2025Q1, the Other revenue business generated the highest revenue for Tvardi Therapeutics Ord Shs, amounting to 1.32M and accounting for 51.50% of total revenue.
